A Phase 1/2, Multicenter, Dose-Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of TH-302 in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma.
Phase of Trial: Phase I/II
Latest Information Update: 27 Sep 2017
At a glance
- Drugs Evofosfamide (Primary) ; Doxorubicin
- Indications Soft tissue sarcoma
- Focus Adverse reactions
- Sponsors Threshold Pharmaceuticals
- 03 May 2012 Planned End Date changed from 1 Dec 2011 to 1 Dec 2012.
- 28 Oct 2011 Results were reported at the Connective Tissue Oncology Society Meeting, according to a Threshold Pharmaceuticals media release.
- 03 Aug 2011 Planned end date (Dec 2011) added as reported by ClinicalTrials.gov.